Researchers from the University of Oslo (UiO), Akershus University Hospital (Ahus), and international collaborators have published a new expert review in Nature Aging. The paper brings together more than 25 scientists, including clinicians and leading experts in aging biology and metabolism, with a strong focus on nicotinamide adenine dinucleotide (NAD+). Their combined insights highlight a growing global effort to understand how this small molecule may support healthier aging and help protect against conditions like Alzheimer's and Parkinson's disease.
NAD+ is often called a cell's "fuel regulator" because it plays a central role in producing energy, repairing DNA, and keeping cells working properly. However, NAD+ levels naturally decrease as people age. This decline has been linked to memory problems, reduced muscle strength, and a higher risk of age-related diseases.
"Fine-tuning NAD+ metabolism holds promise for delaying age-related health decline as well as disease such as premature ageing diseases," says Dr. Jianying Zhang, one of the lead authors. "But to truly unlock its potential, we need to better understand the right doses, long-term safety, and interindividual variability in response to NAD+ augmentation strategies."
To read more, click here.